Market Newsdesk

April 23, 2025 11:28 am

Concorde International Group Announces Closing of $5,000,000 Initial Public Offering

Singapore, April 23, 2025 (GLOBE NEWSWIRE) — Concorde International Group Ltd. (NASDAQ: CIGL) (“Concorde” or the “Company”), an integrated security services provider that combines physical manpower and innovative technology to deliver effective security solutions, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$4.00 per share for total gross proceeds of US$5.0 million, before deducting underwriting discounts and other offering expenses. The Offering closed on April 23, 2025 and the Class A Ordinary Shares began trading on Nasdaq Capital Market on April 22, 2025, under the ticker symbol “CIGL.”

The Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Class A Ordinary Shares at the public offering price, less underwriting discounts.

The Company intends to use the net proceeds from this Offering for or purchase and rollout of electric vehicular mobile command centers, research and development activities, regional market development and exploration of new markets, product development, working capital and general corporate purposes.

The Offering was conducted on a firm commitment basis. R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) acted as sole book-running manager for the Offering.

A registration statement on Form F-1 (File No. 333-281799) relating to the Offering, as amended, was filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on March 31, 2025. The Offering was made only by means of a prospectus, forming a part of the registration statement, and a free writing prospectus. Copies of the final prospectus related to the Offering may be obtained from R.F. Lafferty by email at [email protected] or via standard mail to R.F. Lafferty & Co., Inc, 40 Wall Street, 27th Floor, New York, NY10005. In addition, a copy of the final prospectus can also be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus, the free writing prospectus, and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Concorde International Group Ltd

Concorde International Group Limited (Nasdaq: CIGL) is a Singapore-based company specializing in integrated security solutions and facilities management services. Established in 1997, the Company has transitioned from traditional security services to a technology-driven approach. This shift involves deploying advanced systems like CCTV, sensors, and mobile command vehicles, significantly reducing the need for physical guards and enhancing operational efficiency.

For more information, please visit: https://www.concordesecurity.com/.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, contact:

Investor Relations Contact:

Crescendo Communications, LLC
David Waldman/Natalya Rudman
Tel: (212) 671-1020
Email: [email protected]

April 23, 2025 11:25 am

Gold Miners See Renewed Momentum as Precious Metal Hits New Highs

PR Newswire

Equity Insider

News Commentary

Issued on behalf of Lake Victoria Gold Ltd.

VANCOUVER, BC., April 23, 2025 /PRNewswire/ — Equity InsiderNews Commentary – If you thought that gold prices setting new records was enough to keep the bulls happy, think again. Now a gold analyst backed by an endorsement from Canadian billionaire mining investor Eric Sprott is predicting a “once-in-a-generation” bull run for mining stocks. Gold stock analyst Don Durrett believes gold equities are “unbelievably mispriced” in current markets, and is citing his valuation model that projects gold could surge to $4,000 per ounce. Major banks, including UBS and Deutsche Bank have already revised their gold price projections to $3,500 and $3,700 respectively. Even Goldman Sachs sees a $3,700 gold price this year, as some gold mining stocks have double in the last year. On the ground, miners are making gains in the current market, with important development coming from Lake Victoria Gold(TSXV: LVG) (OTCQB: LVGLF), TRX Gold Corporation (NYSE-American: TRX) (TSX: TRX), Orezone Gold Corporation (TSX: ORE) (OTCQX: ORZCF), Torex Gold Resources Inc. (TSX: TXG) (OTCPK: TORXF), and i-80 Gold Corp. (TSX: IAU) (NYSE: IAUX).

Gold mining stocks have been steadily gaining ground alongside the precious metal’s historic run. While large-cap miners have seen their stock prices pop off, several junior exploration companies are also making headlines with encouraging drill results that can offer amplified exposure to rising gold prices.

Lake Victoria Gold(TSXV: LVG) (OTCQB: LVGLF) is quietly progressing one of East Africa’s most intriguing new gold stories. Over the past twelve months, the company has cleared key regulatory hurdles, raised critical capital, and lined up a near-term path to production—all while holding long-term upside in one of the continent’s key gold regions.

The company’s highly promising Tembo Project sits next to Barrick’s massive Bulyanhulu Mine in Tanzania’s Lake Victoria Goldfield. A total of US$28 million in historical exploration has already been invested here, including over 50,000 meters of drilling, outlining several high-grade zones that remain open at depth and along strike. Historical intercepts have confirmed mineralized corridors at Ngula 1, Nyakagwe Village, and Nyakagwe East—all showing signs of scale and grade that could potentially drive future growth.

“We believe Tembo represents a rare opportunity to define a new gold camp in one of Tanzania’s most historically productive districts,” said Simon Benstead, Executive Chairman of Lake Victoria Gold. “With multiple exploration and development levers available to us, and a supportive regulatory environment, we’re committed to responsibly unlocking the full value of this high-potential asset.”

Importantly, in March 2025, Lake Victoria Goldcompleted the conversion of its Prospecting License at Tembo into four Mining Licenses—a significant de-risking milestone that grants the company the legal right to mine for the next 10 years, with renewal options. This breakthrough clears the way for development planning and potential fast-tracking of shallow, high-grade zones into potentially early-stage production scenarios.

“The approval of our Mining Licenses is a pivotal step forward for the Tembo Project,” said Marc Cernovitch, President & CEO of Lake Victoria Gold. “We have always believed in the district-scale potential of this asset. With tenure now secured for the next 10 years, we can focus on evaluating the most efficient development options to unlock maximum shareholder value.”

While Tembo may carry the long-term potential, the Imwelo Project may be first to cross the production line. In February, Lake Victoria Goldcompleted its acquisition of the Imwelo Mining License, a key step that brought the project under full control and opens the door to near-term production planning.

The Imwelo Project has already received Tanzanian Mining Commission approval as a mining operation and is positioned to serve as LVG’s potential near-term production asset. Production from Imwelo could generate early cash flow while the company ramps up Tembo for larger-scale development.

In parallel, LVG has been building out financial and strategic flexibility. In late 2024, the company signed a non-binding gold prepay term sheet for up to 7,000 ounces with Monetary Metals—a US based gold bank. Once all conditions precedent are met this gold loan could assist in financing construction costs. Based on this week’s +$3,300 per ounce gold price, that 7,000 ounces would account for ~$23 million.

Back when it acquired Imwelo, the deal came with a three-tranche investment option to invest further with TAIFA Group, headed by one of Tanzania’s wealthiest men. The first tranche was completed in late February, consisting of C$3.52 million, at a share price of C$0.22.

Through the TAIFA connection, LVG addedRichard Reynolds, former CEO of Taifa Mining, to its board of directors, strengthening ties with regional stakeholders and adding operational depth at the board level.

Further upside may still come from the company’s 2021 deal with Barrick. In that transaction, LVG sold six non-core licenses adjacent to Tembo for $6 million upfront, with up to $45 million in contingent payments tied to discoveries. Barrick has since been actively drilling on that ground, with LVG retaining success-based upside without spending a cent.

Between a fast-tracked path to first gold at Imwelo, district-scale upside at Tembo, and a Barrick-adjacent land package still generating potential, Lake Victoria Gold has positioned itself as one of the more interesting junior gold developers operating in East Africa today.

CONTINUED… Read this and more news for Lake Victoria Gold at:

https://equity-insider.com/2025/04/14/with-funding-commitments-in-place-a-gold-mine-is-being-built-and-this-stock-is-still-under-0-20/

In other industry developments and happenings in the market include:

TRX Gold Corporation (NYSE-American: TRX) (TSX: TRX) recently reported Q2 2025 revenue of $9.1 million and $2 million in operating cash flow, driven by a record gold price of $2,739/oz and lower per-tonne processing costs. Although gold output declined due to planned mine sequencing, production is already trending higher heading into Q3.

“The past couple of years have set the foundation for continued growth at Buckreef Gold,” said Stephen Mullowney, CEO of TRX. “We have significantly de-risked Buckreef Gold’s operations, building production capacity on-time and on-budget… This is exciting, stay tuned!”

TRX has unveiled strong drill results at the emerging Stamford Bridge Zone and is preparing a new growth-focused business plan for the Buckreef Project. With a larger-scale mine study expected later this year, the company is positioning itself for significant operational and resource upside.

Orezone Gold Corporation (TSX: ORE) (OTCQX: ORZCF) recently reported it produced 28,688 ounces of gold in Q1-2025 and generated $82.5 million in sales, supported by a strong average realized price of $2,851 per ounce. The company also hit a major safety milestone and remains ahead of schedule and on budget with its Stage I hard rock expansion at the Bomboré Mine, which is on track for commissioning in Q4. Once complete, the expansion is expected to boost annual gold production by roughly 45% starting in 2026.

“Q1 was another solid operating quarter at Bomboré, with slightly lower than planned gold ounces produced as a result of re-scheduled mill maintenance,” said Patrick Downey, President and CEO of Orezone. “Mined tonnage was ahead of plan for the quarter, which keeps the Company well-positioned to achieve its 2025 production guidance of 115,000-130,000 ounces.”

Torex Gold Resources Inc. (TSX: TXG) (OTCPK: TORXF) recently reported that it produced 58,330 ounces of gold in Q1 2025 and sold 59,756 ounces, despite a scheduled four-week plant tie-in that temporarily reduced output. With those upgrades complete and concentrate shipments underway, the company expects a material production increase in Q2 and remains on track to meet full-year guidance of 400,000 to 450,000 gold equivalent ounces.

“A number of significant milestones were achieved during Q1 2025, and we are incredibly proud of these accomplishments,” said Jody Kuzenko, President and CEO of Torex. “With many of the key transition risks now behind us, we remain on track to achieve payable production at our guided range of 400,000 to 450,000 oz AuEq.”

As mining rates ramp up at the Media Luna and ELG underground zones, Torex is entering a growth phase with free cash flow expected to resume shortly.

i-80 Gold Corp. (TSX: IAU) (NYSE: IAUX) recently reported it’s advancing its position as a major Nevada gold developer, ahead of confirming the filing of file eight technical reports, covering its core projects including Cove, Archimedes, Mineral Point, and Granite Creek. These reports follow PEAs released earlier this year and highlight the company’s multi-asset development pipeline in some of Nevada’s most prolific gold belts.

The company is also finalizing its transition to U.S. GAAP accounting and will report its 2024 financials and 10-K on the same date. With a fully permitted central processing facility and a hub-and-spoke model in place, i-80 Gold aims to become a significant mid-tier U.S. gold producer.

Article Source:

https://equity-insider.com/2025/04/14/with-funding-commitments-in-place-a-gold-mine-is-being-built-and-this-stock-is-still-under-0-20/

CONTACT:

Equity Insider

[email protected]

(604) 265-2873

DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca media corp, who has been paid a fee for an advertising from a shareholder of the Company (333,333 unrestricted shares). MIQ has not been paid a fee for Lake Victoria Gold Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (“BAY”) There may also be 3rd parties who may have shares of Lake Victoria Gold Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Lake Victoria Gold Ltd and reserve the right to buy and sell, and will buy and sell shares of Lake Victoria Gold Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions (SACNASP) and is a Director of Lake Victoria Gold Ltd., and therefore is not independent of the Company; this is a paid advertisement, we currently own shares of Lake Victoria Gold Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Logo – https://mma.prnewswire.com/media/2644233/5282615/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/gold-miners-see-renewed-momentum-as-precious-metal-hits-new-highs-302436062.html

SOURCE Equity Insider

April 23, 2025 11:25 am

El Mayor Tequila debuts new packaging

PR Newswire

The award-winning tequila will now be packaged in a new slim bottle with an updated label

ST. LOUIS
, April 23, 2025 /PRNewswire/ — El Mayor Tequila – the award-winning premium tequila from the Gonzalez family – is getting a new look. Starting this month and continuing throughout 2025, the El Mayor Tequila brand family will be packaged in a new 750 mL bottle that features a larger label that creates a cohesive look across the brand portfolio and provides a more impactful footprint for shelf placement.

Distilled and produced at Destiladora Gonzalez Lux in Arandas, Mexico, El Mayor Tequila is made with 100% estate-grown Blue Weber Agave from the valley area of Jalisco, Mexico. Current offerings include:

El Mayor Tequila Blanco – this unaged clear tequila offers a crisp, light body, with a hint of floral and pepper.
El Mayor Tequila Reposado – rested in white oak barrels for a minimum of nine months, this golden tequila delivers hints of fruit flavors with vanilla and spice.
El Mayor Tequila Rosado Reposado – this premium reposado tequila is finished in Cabernet Sauvignon casks for nine months to create a rich, smooth-tasting tequila with a hint of spiced-berry flavor.
El Mayor Tequila Añejo – designed for slow, contemplative sipping, this tequila is aged in white oak barrels for 18 to 36 months to provide a sophisticatedly smooth product with notes of caramel, grilled fruits and brown spices.
EL Mayor Tequila Extra Añejo – meticulously aged in American white oak barrels for a minimum of three-and-a-half years for a rich, complex flavor profile, this tequila offers notes of wood, caramel, dark chocolate and hazelnut.
El Mayor Tequila Cristalino – this Añejo tequila has been aged for a minimum of 12 months and filtered using ultra fine charcoal to create a tequila with the complexity and character of an Añejo and the crisp, bright notes and color of a Blanco.

“We wanted to ensure consumers could easily find and identify our various El Mayor offerings on the crowded tequila shelf,” said Brand Manager Kayleigh Longo. “We were already using the slim bottle for our Cristalino and for our new Rosado Reposado tequila, so we made the decision to incorporate the same packaging for all our El Mayor expressions to create a consistent brand look and feel.”

The brand’s recent recognition includes gold medals at the ASCOT and SIP Awards for El Mayor Tequila Blanco; a double gold medal at the San Francisco World Spirits Competition and a gold medal at the SIP Awards for El Mayor Tequila Reposado; a double platinum and Best In Category honor at the ASCOT Awards for El Mayor Tequila Añejo; a gold medal at the ASCOT Awards for El Mayor Tequila Extra Añejo, and a platinum medal at the SIP Awards for El Mayor Tequila Cristalino. In addition, El Mayor Tequila Reposado was recently recognized as one of the top 10 tequilas in the world at the 2025 International Wines and Spirits Competition (IWSC).

For recipes and more information about El Mayor Tequila, or to find a retailer, visit ElMayor.com or follow the brand @elmayortequila on Facebook and Instagram.

About El Mayor Tequila
Distilled and produced at Destiladora Gonzalez Lux in Arandas, Mexico, award-winning premium El Mayor Tequila is made with 100% estate-grown Blue Weber Agave from the valley area of Jalisco, Mexico. Led by fourth-generation Master Distiller Graciela Gonzalez, the El Mayor Tequila portfolio is crafted with the tradition, methodology and passion of the Gonzalez family’s more than 150-year heritage and includes Blanco, Reposado, Rosado Reposado, Añejo, Extra Añejo and Cristalino. Our expressions have earned prestigious industry acclaim including gold at the 2024 SIP Awards, double gold at the 2024 San Francisco World Spirits Competition and recognition as one of the top 10 tequilas in the world at the 2025 International Wines and Spirits Competition for El Mayor Reposado. To learn more, visit ElMayor.com and follow on Facebook and Instagram.

About Luxco
Founded in St. Louis in 1958 by the Lux family, Luxco is a leading producer, supplier, importer and bottler of beverage alcohol products with a mission to meet the needs and exceed the expectations of consumers, associates and business partners. Luxco operates as MGP Ingredients Inc. (Nasdaq: MGPI) Branded Spirits division since its acquisition in 2021. The company’s extensive and award-winning premium portfolio includes brands from four distilleries: Ross & Squibb Distillery in Lawrenceburg, Indiana, where Penelope and Remus bourbon are produced; Bardstown, Kentucky-based Lux Row Distillers, home of Rebel, Ezra Brooks, and Blood Oath bourbons; Lebanon, Kentucky-based Limestone Branch Distillery, maker of Yellowstone Bourbon; and Arandas, Mexico-based Destiladora Gonzalez Lux, producer of 100% agave tequilas including El Mayor and Exotico. For more information, visit Luxco.com.

CONTACT:

Patrick Barry, BYRNE PR
314-540-3865
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/el-mayor-tequila-debuts-new-packaging-302436061.html

SOURCE El Mayor Tequila

April 23, 2025 11:18 am

Lawsuit for Investors in shares of The Trade Desk, Inc. (NASDAQ: TTD) announced by the Shareholders Foundation

PR Newswire

SAN DIEGO
, April 23, 2025 /PRNewswire/ — The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of the Trade Desk, Inc. (NASDAQ: TTD).

Investors who purchased shares of The Trade Desk, Inc. (NASDAQ: TTD) prior to May 2024 and continue to hold any of those NASDAQ: TTD shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

On February 19, 2025, a NASDAQ: TTD investor filed a lawsuit over alleged securities laws violations by The Trade Desk, Inc. The plaintiff alleged that between May 09, 2024 and February 12, 2025, defendants made materially false and misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects, including that Trade Desk was experiencing significant, ongoing, self-inflicted execution challenges rolling out Kokai, including transitioning clients to Kokai from the Company’s older platform Solimar, that such execution challenges meaningfully delayed the Kokai Rollout, that Trade Desk’s inability to effectively execute the Kokai Rollout negatively impacted the Company’s business and operations, particularly revenue growth, and that as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of The Trade Desk, Inc. (NASDAQ: TTD) should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-for-investors-in-shares-of-the-trade-desk-inc-nasdaq-ttd-announced-by-the-shareholders-foundation-302435471.html

SOURCE Shareholders Foundation, Inc.

April 23, 2025 11:06 am

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

WILMINGTON, Del.–(BUSINESS WIRE)–
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago.

“The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipeline, reflect our ongoing efforts to transform cancer care,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We are advancing potential therapies across some of the most difficult-to-treat cancers and hematological diseases, including squamous cell anal cancer, ovarian cancer and myelofibrosis, with the hope of making a meaningful difference for these patients.”

Key abstracts accepted for presentation:

Oral Presentations

INCB123667

Safety and Preliminary Efficacy from a Phase 1 Study of INCB123667, a Selective CDK2 Inhibitor, in Patients with Advanced Platinum-Resistant and Refractory Ovarian Cancer (OC)

(Abstract #5514. Session: Rapid Oral Abstract – Gynecologic Cancer. June 3, 9:42 a.m. ET (8:42 a.m. CT))

Pemigatinib

A Phase 2 Study of Pemigatinib for Pre-treated Glioblastoma or Other Gliomas with Activating FGFR1-3 Alterations: Results from FIGHT-209

(Abstract #2003. Session: Oral Abstract Session – Central Nervous System Tumors. May 30, 4:21 p.m. ET (3:21 p.m. CT))

Poster Presentations

Retifanlimab

Experience of Patients with HIV and Squamous Cell Carcinoma of the Anal Canal (SCAC) Treated with Retifanlimab

(Abstract #3521. Session: Gastrointestinal Cancer—Colorectal and Anal. May 31, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT))

POD1UM-303/INTERAACT2 Subgroup Analyses and Impact of Delayed Retifanlimab Treatment on Outcomes in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

(Abstract #3525. Session: Gastrointestinal Cancer—Colorectal and Anal. May 31, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT))

Final Results of POD1UM-201, a Phase 2 Study of Retifanlimab, a Humanized Anti–PD-1 Antibody, in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC)

(Abstract #9536. Session: Melanoma/Skin Cancers. June 1, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT))

Long-term Outcomes After Discontinuation of Retifanlimab in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC) in the POD1UM-201 Trial

(Abstract #9538. Session: Melanoma/Skin Cancers. June 1, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT))

INCB123667

Interim Safety and Antitumor Activity Data from a Phase 1 Study of INCB123667, a Selective CDK2 Inhibitor, in Patients with Metastatic Recurrent Endometrial Cancer

(Abstract #5603. Session: Gynecologic Cancer. June 1, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT))

INCB057643

Safety And Efficacy of Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 In Patients (pts) with Relapsed or Refractory Myelofibrosis (r/r-MF) and Other Advanced Myeloid Neoplasms: A Phase (Ph) 1 Study

(Abstract #6574. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. June 1, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT))

More information regarding the 2025 ASCO Annual Meeting can be found at: https://conferences.asco.org/am/abstracts.

About Pemazyre^® (pemigatinib)

Pemazyre^® (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test*. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Pemazyre is also the first targeted treatment approved for use in the United States for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.

In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a FGFR2 fusion gene, worsening after cancer chemotherapy.

In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

In Canada, Pemazyre is approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

Pemazyre is marketed by Incyte in the United States, Europe, Japan and Canada.

Pemazyre and the Pemazyre logo are registered trademarks of Incyte.

* Pemazyre^® (pemigatinib) [Package Insert]. Wilmington, DE: Incyte; 2020.

About Zynyz^® (retifanlimab-dlwr)

Zynyz^® (retifanlimab-dlwr), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

In Europe, Zynyz (retifanlimab) is approved as a monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced MCC not amenable to curative surgery or radiation therapy.

In Canada, Zynyz (retifanlimab) is approved as monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced MCC not amenable to curative surgery or radiation therapy.

Zynyz is marketed by Incyte in the U.S., Europe and Canada, in 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.

Zynyz is a registered trademark of Incyte.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Incyte Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, and Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners’ products; the acceptance of Incyte and its partners’ products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-K for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422904369/en/

Media

[email protected]

Investors

[email protected]

KEYWORDS: Europe United States North America Illinois Delaware

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo

April 23, 2025 11:05 am

Sun Country Airlines Will Hold Its First Quarter 2025 Earnings Conference Call May 2

MINNEAPOLIS, April 23, 2025 (GLOBE NEWSWIRE) — Sun Country Airlines (NASDAQ: SNCY) will hold its first quarter 2025 earnings call on Friday, May 2 at 8:30 a.m. Eastern Time.

To access the live call and subsequent replay, interested investors and other parties can log on to the Sun Country investor relations website at https://ir.suncountry.com/news-events/events-and-presentations. They may also access the call by clicking on the link here which will provide a dial-in.

About Sun Country

Sun Country Airlines is a new breed of hybrid low-cost air carrier, whose mission is to connect guests to their favorite people and places, to create lifelong memories and transformative experiences. Sun Country dynamically deploys shared resources across our synergistic scheduled service, charter, and cargo businesses. Based in Minnesota, we focus on serving leisure and visiting friends and relatives (“VFR”) passengers and charter customers and providing cargo service to Amazon, with flights throughout the United States and to destinations in Mexico, Central America, Canada, and the Caribbean.

For photos, b-roll and additional company information, visit https://www.stories.suncountry.com/multimedia.

Investor Relations
Chris Allen
[email protected]

April 23, 2025 11:03 am

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Welltower Inc. (NYSE: WELL)

PR Newswire

NEW YORK
, April 23, 2025 /PRNewswire/ — Purcell & Lefkowitz LLP announces that it is investigating Welltower Inc. (NYSE: WELL) on behalf of the company’s shareholders. The investigation seeks to determine whether Welltower’s directors breached their fiduciary duties in connection with recent corporate actions.

If you are a shareholder of Welltower and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/welltower-inc/

You may also contact Robert H. Lefkowitz, Esq. either via email at [email protected] or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.

Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome.

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-purcell–lefkowitz-llp-announces-shareholder-investigation-of-welltower-inc-nyse-well-302435804.html

SOURCE Purcell & Lefkowitz LLP

April 23, 2025 11:03 am

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)

PR Newswire

NEW YORK
, April 23, 2025 /PRNewswire/ — Purcell & Lefkowitz LLP announces that it is investigating BridgeBio Pharma, Inc. (NASDAQ: BBIO) on behalf of the company’s shareholders. The investigation seeks to determine whether BridgeBio Pharma’s directors breached their fiduciary duties in connection with recent corporate actions.

If you are a shareholder of BridgeBio Pharma and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/bridgebio-pharma-inc/

SOURCE Purcell & Lefkowitz LLP

April 23, 2025 11:03 am

Vishay Intertechnology Thick Film Power Resistor With Optional NTC Thermistor and PC-TIM Simplifies Designs and Saves Board Space

AEC-Q200 Qualified Device in Compact SOT-227B Package Offers High Pulse Handling Capability and Power Dissipation to 200 W

MALVERN, Pa., April 23, 2025 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new AEC-Q200 qualified thick film power resistor in the compact, low profile SOT-227B package for mounting on a heatsink. Available with an optional NTC thermistor for internal temperature monitoring and pre-applied Phase Change Thermal Interface Material (PC-TIM) for more efficient mounting, the Vishay MCB ISOA200 offers high pulse handling capability and high power dissipation up to 200 W at an 80 °C bottom case temperature.

Built on an exposed alumina substrate instead of a metal tab, the device released today lowers costs and weight for automotive, industrial, and avionics, military, and space (AMS) applications, in which it will serve as a precharge, discharge, active discharge, or snubber resistor. For applications subject to high and repetitive pulse surges, the resistor can handle high energy pulses up to 140 J for 0.1 s and is multi-pulsed tested. Additional custom testing options for the device are also available.

With the option to integrate an AEC-Q200 qualified, temperature cycle tested NTC thermistor inside the resistor package, the ISOA200 simplifies designs and saves board space, while its optional PC-TIM streamlines installation in production. The device’s high power and high energy dissipation further simplify designs while lowering costs by reducing the need for power components.

The ISOA200 features a resistance range from 10 Ω to 1 MΩ, with tolerances of ± 5 % and ± 10 %, and TCR of ± 100 ppm/K and ± 150 ppm/K. The resistor offers a maximum operating voltage of 1500 V, an operating temperature range of -55 °C to +150 °C, and dielectric strength of 4000 Vrms. The RoHS-compliant device offers a non-inductive design and can include two different resistors.

Samples and production quantities of the new resistor are available now, with lead times of 12 weeks.

Vishay manufactures one of the world’s largest portfolios of discrete semiconductors and passive electronic components that are essential to innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and medical markets. Serving customers worldwide, Vishay is The DNA of tech.^® Vishay Intertechnology, Inc. is a Fortune 1000 Company listed on the NYSE (VSH). More on Vishay at www.Vishay.com.

The DNA of tech
^® is a registered trademark of Vishay Intertechnology, Inc.

Vishay on Facebook:
http://www.facebook.com/VishayIntertechnology

Vishay Twitter feed:
http://twitter.com/vishayindust

Link to product datasheet:

http://www.vishay.com/ppg?32607 (ISOA200)

Link to product photo:

https://www.flickr.com/photos/vishay/albums/72177720325191869

For more information please contact:

Vishay Intertechnology
Peter Henrici, +1 408 567-8400
[email protected]
or
Redpines
Bob Decker, +1 415 409-0233
[email protected]

April 23, 2025 11:03 am

Piper Sandler Companies to Announce First Quarter 2025 Financial Results and Host a Conference Call on May 2, 2025

Piper Sandler Companies to Announce First Quarter 2025 Financial Results and Host a Conference Call on May 2, 2025

MINNEAPOLIS–(BUSINESS WIRE)–Piper Sandler Companies (NYSE: PIPR), a leading investment bank, will release its first quarter 2025 financial results prior to the opening of the market on Friday, May 2, 2025. The earnings release will be available at the company’s website at pipersandler.com/earnings.

Chad Abraham, chairman and chief executive officer; Deb Schoneman, president; and Kate Clune, chief financial officer, will host a related conference call at 8 a.m. ET (7 a.m. CT) that same day to review the financial results. There will be a question and answer session following the review.

Investors and analysts may participate in the live conference call by dialing 888 394-8218 (in the U.S.) or +1 773 305-6853 (outside the U.S.) and passcode 9183623. Please dial in at least 15 minutes prior to the call time.

A live audio webcast of the conference call will be available through the company’s website at pipersandler.com/earnings. A replay of the conference call will be available after the event through the same link.

Please direct any questions regarding obtaining access to the conference call to Piper Sandler Investor Relations, via email, at [email protected].

ABOUT PIPER SANDLER

Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; in the EU through Aviditi Capital Advisors Europe GmbH, authorized and regulated by BaFin as a tied agent of AHP Capital Management GmbH; and in Hong Kong through Piper Sandler Hong Kong Ltd., authorized and regulated by the Securities and Futures Commission. Alternative asset management and fixed income advisory services are offered through separately registered advisory affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250423758732/en/

Kate Clune

Tel: 212 466-7799

[email protected]

KEYWORDS: United States North America Minnesota

INDUSTRY KEYWORDS: Banking Accounting Professional Services Finance

MEDIA:

Logo